{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T14:47:27Z","timestamp":1770043647729,"version":"3.49.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T00:00:00Z","timestamp":1749945600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T00:00:00Z","timestamp":1749945600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Obes"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background\/Objectives<\/jats:title>\n            <jats:p>Obesity treatment can produce variable outcomes for different individuals. The aim of this analysis in adolescents with obesity was to investigate if baseline participant characteristics associated with BMI reduction from baseline to 56 weeks when treated with mid- or top-dose phentermine\/topiramate (PHEN\/TPM) compared to placebo.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A secondary analysis of a randomized, double-blind, placebo-controlled, clinical trial evaluating PHEN\/TPM in adolescents with obesity was conducted. Participants, aged 12 to &lt;17 years with a BMI <jats:underline>\u2265<\/jats:underline>95th percentile, were randomly assigned in a 1:1:2 ratio to receive either placebo, mid-dose (PHEN\/TPM 7.5\u2009mg\/46\u2009mg) or top-dose (PHEN\/TPM 15\u2009mg\/92\u2009mg). Baseline characteristics included in the analysis were BMI, age, sex, race\/ethnicity, pubertal status, diabetes status, depression status, cognitive function score, and quality of life score. The primary analysis used linear regression with BMI percent change from baseline to 56 weeks as the outcome with either mid- or top-dose PHEN\/TPM compared to placebo.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Two-hundred twenty-two participants were included in the final analysis. None of the baseline characteristics were statistically significantly associated with BMI reduction with mid- or top-dose PHEN\/TPM compared to placebo.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Baseline characteristics were not predictive of BMI reduction with either dose of PHEN\/TPM compared to placebo in adolescents with obesity.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1038\/s41366-025-01821-6","type":"journal-article","created":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T02:49:14Z","timestamp":1749955754000},"page":"1777-1780","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Predictors of BMI reduction with phentermine\/topiramate in adolescents with obesity"],"prefix":"10.1038","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9341-1858","authenticated-orcid":false,"given":"Megan O.","family":"Bensignor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca L.","family":"Freese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyle D.","family":"Rudser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron S.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia","family":"Kunin-Batson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2809-8460","authenticated-orcid":false,"given":"Amy C.","family":"Gross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5858-2080","authenticated-orcid":false,"given":"Carolyn","family":"Bramante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Winnie","family":"Shih","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5732-0062","authenticated-orcid":false,"given":"Claudia K.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,15]]},"reference":[{"key":"1821_CR1","doi-asserted-by":"publisher","unstructured":"Hampl SE, Hassink SE, Skinner AC, Armstrong SC, Barlow SE, Bolling CF, et al. Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity. Pediatrics. 2023;151:e2022060640. https:\/\/doi.org\/10.1542\/peds.2022-060640.","DOI":"10.1542\/peds.2022-060640"},{"key":"1821_CR2","doi-asserted-by":"publisher","unstructured":"Emmerich SD, Fryar CD, Stierman B, Gu Q, Afful J, Ogden CL. Trends in obesity-related measures among US children, adolescents, and adults. JAMA. 2025:e2427676. https:\/\/doi.org\/10.1001\/jama.2024.27676.","DOI":"10.1001\/jama.2024.27676"},{"key":"1821_CR3","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1916038","volume":"382","author":"AS Kelly","year":"2020","unstructured":"Kelly AS, Auerbach P, Barrientos-Perez M, Gies I, Hale PM, Marcus C, et al. A randomized, controlled trial of liraglutide for adolescents with obesity. N Engl J Med. 2020;382:2117\u201328.","journal-title":"N Engl J Med"},{"key":"1821_CR4","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1001\/2013.jamapediatrics.319","volume":"166","author":"P Danielsson","year":"2012","unstructured":"Danielsson P, Kowalski J, Ekblom \u00d6, Marcus C. Response of severely obese children and adolescents to behavioral treatment. Arch Pediatr Adolesc Med. 2012;166:1103\u20138.","journal-title":"Arch Pediatr Adolesc Med"},{"key":"1821_CR5","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.jpeds.2010.09.049","volume":"158","author":"CA Johnston","year":"2011","unstructured":"Johnston CA, Tyler C, Palcic JL, Stansberry SA, Gallagher MR, Foreyt JP. Smaller weight changes in standardized body mass index in response to treatment as weight classification increases. J Pediatr. 2011;158:624\u20137.","journal-title":"J Pediatr"},{"key":"1821_CR6","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1002\/oby.22369","volume":"27","author":"JR Ryder","year":"2019","unstructured":"Ryder JR, Kaizer AM, Jenkins TM, Kelly AS, Inge TH, Shaibi GQ. Heterogeneity in response to treatment of adolescents with severe obesity: the need for precision obesity medicine. Obesity. 2019;27:288\u201394.","journal-title":"Obesity"},{"key":"1821_CR7","unstructured":"Novo Nordisk. FDA approves once-weekly Wegovy\u00ae injection for the treatment of obesity in teens aged 12 years and older. 2022. https:\/\/www.novonordisk-us.com\/media\/news-archive\/news-details.html?id=151389."},{"key":"1821_CR8","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S2352-4642(19)30236-6","volume":"3","author":"F Bacha","year":"2019","unstructured":"Bacha F. FDA approval of GLP-1 receptor agonist (liraglutide) for use in children. Lancet Child Adolesc Health. 2019;3:595\u20137. https:\/\/doi.org\/10.1016\/S2352-4642(19)30236-6.","journal-title":"Lancet Child Adolesc Health"},{"key":"1821_CR9","unstructured":"U.S. Food and Drug Administration. Orlistat (marketed as Allli and Xenical) information. 2015. https:\/\/www.fda.gov\/drugs\/postmarket-drug-safetyinformation-patients-and-providers\/orlistat-marketed-alli-and-xenical information#:~:text=Xenical%20(orlistat%20120mg)%20was%20approved,weight%20after%20prior%20weight%20loss."},{"key":"1821_CR10","unstructured":"U.S. Food and Drug Administration. Highlights of prescribing information: Qsymia (phentermine and topiramate extended-release). 2013. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/022580Orig1s000LBL.pdf."},{"key":"1821_CR11","doi-asserted-by":"crossref","unstructured":"Kelly AS, Bensignor MO, Hsia DS, Shoemaker AH, Shih W, Peterson C, et al. Phentermine\/topiramate for the treatment of adolescent obesity. NEJM Evid. 2022;1:1\u201311.","DOI":"10.1056\/EVIDoa2200014"},{"key":"1821_CR12","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.2337\/dc24-S002","volume":"47","author":"American Diabetes Association Professional Practice Committee.","year":"2024","unstructured":"American Diabetes Association Professional Practice Committee. 2. Diagnosis and classification of diabetes: standards of care in diabetes-2024. Diabetes Care. 2024;47:S20\u201342. https:\/\/doi.org\/10.2337\/dc24-S002.","journal-title":"Diabetes Care"},{"key":"1821_CR13","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1089\/cap.2018.0112","volume":"29","author":"AL Nandakumar","year":"2019","unstructured":"Nandakumar AL, Vande Voort JL, Nakonezny PA, Orth SS, Romanowicz M, Sonmez AI, et al. Psychometric properties of the Patient Health Questionnaire-9 Modified for major depressive disorder in adolescents. J Child Adolesc Psychopharmacol. 2019;29:34\u201340.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"1821_CR14","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1590\/S1980-57642011DN05020012","volume":"5","author":"RAA Teixeira","year":"2011","unstructured":"Teixeira RAA, Zachi EC, Roque DT, Taub A, Ventura DF. Memory span measured by the spatial span tests of the Cambridge Neuropsychological Test Automated Battery in a group of Brazilian children and adolescents. Dement Neuropsychol. 2011;5:129\u201334.","journal-title":"Dement Neuropsychol"},{"key":"1821_CR15","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/oby.2006.59","volume":"14","author":"RL Kolotkin","year":"2006","unstructured":"Kolotkin RL, Zeller M, Modi AC, Samsa GP, Quinlan NP, Yanovski JA, et al. Assessing weight-related quality of life in adolescents. Obesity. 2006;14:448\u201357.","journal-title":"Obesity"},{"key":"1821_CR16","doi-asserted-by":"publisher","first-page":"e13143","DOI":"10.1111\/ijpo.13143","volume":"19","author":"EM Bomberg","year":"2024","unstructured":"Bomberg EM, Clark J, Rudser KD, Gross AC, Kelly AS, Fox CK. Effectiveness and predictors of weight loss response to phentermine plus lifestyle modifications among youth in a paediatric weight management clinical setting. Pediatr Obes. 2024;19:e13143.","journal-title":"Pediatr Obes"},{"key":"1821_CR17","doi-asserted-by":"publisher","first-page":"1369270","DOI":"10.3389\/fendo.2024.1369270","volume":"15","author":"EM Bomberg","year":"2024","unstructured":"Bomberg EM, Clark J, Rudser KD, Gross AC, Kelly AS, Fox CK. Clinical effectiveness and predictors of response to topiramate plus lifestyle modification in youth with obesity seen in a weight management clinical setting. Front Endocrinol. 2024;15:1369270.","journal-title":"Front Endocrinol"},{"key":"1821_CR18","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/oby.2003.78","volume":"11","author":"E Ben-Menachem","year":"2003","unstructured":"Ben-Menachem E, Axelsen M, Johanson EH, Stagge A, Smith U. Predictors of weight loss in adults with topiramate-treated epilepsy. Obes Res. 2003;11:556\u201362.","journal-title":"Obes Res"},{"key":"1821_CR19","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1212\/01.wnl.0000265853.66458.82","volume":"69","author":"SH El Yaman","year":"2007","unstructured":"El Yaman SH, Mroueh SM, Sinno DD, Mikati MA. Long-term patterns of weight changes during topiramate therapy: an observational study. Neurology. 2007;69:310\u20131.","journal-title":"Neurology"},{"key":"1821_CR20","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1136\/jnnp.2007.136929","volume":"79","author":"KM Klein","year":"2008","unstructured":"Klein KM, Theisen F, Knake S, Oertel WH, Hebebrand J, Rosenow F, et al. Topiramate, nutrition and weight change: a prospective study. J Neurol Neurosurg Psychiatry. 2008;79:590\u20133.","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["International Journal of Obesity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41366-025-01821-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41366-025-01821-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41366-025-01821-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T08:24:46Z","timestamp":1758788686000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41366-025-01821-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,15]]},"references-count":20,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["1821"],"URL":"https:\/\/doi.org\/10.1038\/s41366-025-01821-6","relation":{},"ISSN":["0307-0565","1476-5497"],"issn-type":[{"value":"0307-0565","type":"print"},{"value":"1476-5497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,15]]},"assertion":[{"value":"12 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MOB receives research support as donated study drug (VIVUS LLC) and continuous glucose monitoring devices (Abbott Inc). CKF serves as a site PI for Novo Nordisk and Eli Lilly clinical trials. Compensation is paid directly to her institution. ASK engages in unpaid consulting and educational activities, as well as serves as an unpaid investigator for Novo Nordisk; engages in unpaid consulting activities and serves as an unpaid investigator for Boehringer Ingelheim, Eli Lilly, and VIVUS; receives donated drug\/placebo from Novo Nordisk and Vivus for National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)-funded clinical trials. WS and CP are both employees of VIVUS LLC.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The University of Minnesota Institutional Review Board approved this analysis and informed consent was not required for this secondary analysis. The original trial, including all methods, was conducted in accordance with International Council for Harmonisation (ICH) E6 (R2) Good Clinical Practices (GCP) guidelines and the principles of the Declaration of Helsinki. An independent central Institutional Review Board (IRB) in addition to individual site IRBs approved the parent trial protocol.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}